Faculty, Staff and Student Publications

Publication Date

7-22-2024

Journal

The Journal for ImmunoTherapy of Cancer

DOI

10.1136/jitc-2023-008668

PMID

39038917

PMCID

PMC11268062

PubMedCentral® Posted Date

July 2024

PubMedCentral® Full Text Version

Post-print

Abstract

RATIONALE OF THE TRIAL: Although the use of engineered T cells in cancer immunotherapy has greatly advanced the treatment of hematological malignancies, reaching meaningful clinical responses in the treatment of solid tumors is still challenging. We investigated the safety and tolerability of IMA202 in a first-in-human, dose escalation basket trial in human leucocyte antigen A*02:01 positive patients with melanoma-associated antigen A1 (MAGEA1)-positive advanced solid tumors.

TRIAL DESIGN: The 2+2 trial design was an algorithmic design based on a maximally acceptable dose-limiting toxicity (DLT) rate of 25% and the sample size was driven by the algorithmic design with a maximum of 16 patients. IMA202 consists of autologous genetically modified cytotoxic CD8

CONCLUSION: In conclusion, IMA202 had a manageable safety profile, and it was associated with biological and potential clinical activity of MAGEA1-targeting genetically engineered TCR-T cells in a poor prognosis, multi-indication solid tumor cohort.

Keywords

Humans, Female, Male, Antigens, Neoplasm, Middle Aged, Aged, Neoplasms, Adult, Immunotherapy, Adoptive, Receptors, Antigen, T-Cell, Neoplasm Proteins

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.